A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if LY2189265 is safe and effective in reducing
glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2
Diabetes.